Pfizer reported positive topline results from the Phase 3 MagnetisMM-5 trial evaluating ELREXFIO (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma who received at least one prior line of treatment. The study met its primary endpoint at a pre-specified interim analysis, demonstrating a statistically significant improvement in progression-free survival compared with standard-of-care daratumumab plus pomalidomide and dexamethasone (DPd), as assessed by blinded independent central review. The trial enrolled patients whose disease was double-class exposed, meaning they had been treated previously with at least one immunomodulatory drug and one proteasome inhibitor.
According to Pfizer, the progression-free survival results exceeded the pre-specified interim analysis target hazard ratio for efficacy, with most patients treated with ELREXFIO remaining progression-free at the time of the analysis. The safety and tolerability of ELREXFIO in MagnetisMM-5 were consistent with its established safety profile, and no new safety signals were identified. The trial is continuing to assess overall survival, a key secondary endpoint, which was not yet mature at the time of this interim analysis.
MagnetisMM-5 is part of Pfizer’s broader MagnetisMM clinical development program for ELREXFIO in multiple myeloma. The company plans to discuss the Phase 3 results with global health authorities and intends to present detailed data from the study at a future medical congress.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!